NewGenIvf Group Limited Fundamental Analysis (NASDAQ: NIVF)
NewGenIvf Group Limited Fundamental Analysis (NASDAQ: NIVF)
NewGenIvf Group Limited (NASDAQ: NIVF) shows moderate financial fundamentals with a PE ratio of 0.02, profit margin of 3.38%, and ROE of 32.69%. The company generates $0.0B in annual revenue with weak year-over-year growth of -13.01%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 37.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze NIVF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentNIVF demonstrates superior asset utilization.
Valuation Score
ExcellentNIVF trades at attractive valuation levels.
Growth Score
WeakNIVF faces weak or negative growth trends.
Financial Health Score
ExcellentNIVF maintains a strong and stable balance sheet.
Profitability Score
WeakNIVF struggles to sustain strong margins.
Key Financial Metrics
Is NIVF Expensive or Cheap?
P/E Ratio
NIVF trades at 0.02 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NIVF's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values NewGenIvf Group Limited at 0.01 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.41 times EBITDA. This is generally considered low.
How Well Does NIVF Make Money?
Net Profit Margin
For every $100 in sales, NewGenIvf Group Limited keeps $3.38 as profit after all expenses.
Operating Margin
Core operations generate -2.77 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $32.69 in profit for every $100 of shareholder equity.
ROA
NewGenIvf Group Limited generates $27.98 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
NewGenIvf Group Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
NewGenIvf Group Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
NIVF converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.02
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.006
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.06
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.18
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.12
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.33
vs 25 benchmark
ROA
Return on assets percentage
0.28
vs 25 benchmark
ROCE
Return on capital employed
-0.25
vs 25 benchmark
How NIVF Stacks Against Its Sector Peers
| Metric | NIVF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.02 | 29.58 | Better (Cheaper) |
| ROE | 32.69% | 490.00% | Weak |
| Net Margin | 338.20% | -11578.00% (disorted) | Strong |
| Debt/Equity | 0.18 | 0.80 | Strong (Low Leverage) |
| Current Ratio | 3.12 | 5.19 | Strong Liquidity |
| ROA | 27.98% | -131.00% (disorted) | Strong |
NIVF outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews NewGenIvf Group Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-48.84%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
826273.71%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-439.85%
Industry Style: Defensive, Growth, Innovation
Declining